The Association for the Cannabinoid Industry is a membership organisation committed to a safe, legal & well regulated cannabinoid market in the UK. Become a member
Find out how we're strengthening our novel foods consultancy team to help CBD companies meet the FSA's March 31st 2021 deadline
The ACI celebrates our 1st year – here’s a look at what we’ve achieved
The key benchmarks for this are how many people express confidence in the efficacy of our products, and how many would be more likely to do so if there was better regulation.
In that context, the findings from our YouGov survey* are truly illuminating: they are a vindication of why we set up the ACI, launched the ACI charter and committed our members to working towards full novel foods authorisation and standardisation of analytical testing methodologies.
* Methodology: This survey has been conducted using an online interview administered to members of the YouGov Plc UK panel of 800,000+ individuals who have agreed to take part in surveys. Read More
26 Nov, 2020
At this event, that will take place on 9 December 2020, attendees will learn more about the potential of the UK CBD market, how upcoming changes to the UK legal framework could drastically reduce the number of market participants and how established companies can move into this space with the confidence their products are legally compliant.
19 Nov, 2020
The ACI welcomes today’s ruling from the Court of Justice of the European Union (CJEU) which marks a landmark day for the CBD industry.
19 Nov, 2020
The ACI is pleased to announce an additional new hire to enable us to meet the demand from CBD companies seeking guidance from our Regulatory Consultancy Team to finalise their novel foods applications.
23 Nov, 2020
The ruling is a boost to the CBD sector in Europe after the EU decision to potentially classify CBD as a narcotic. The court stated that: ‘A Member State may not prohibit the marketing of cannabidiol (CBD) lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds.’ And that: ‘the provisions on the free movement of goods within the European Union (Articles 34 and 36 TFEU) are applicable, since the CBD at issue in the main proceedings cannot be regarded as a ‘narcotic drug’.’
23 Nov, 2020
The CBD sector is notoriously confusing. Here, the Association for the Cannabinoid Industry offers sound advice for staying ahead and remaining compliant.
20 Nov, 2020
Europe’s CBD market is optimistic a ruling from the EU’s highest court not to classify the ingredient a narcotic – going against the European Commission’s shock preliminary view in July – will pave the way for Novel Food applications for CBD products to re-start.
The Court of Justice of the European Union ruled CBD is not a narcotic drug as it “does not appear to have any psychotropic effect or any harmful effect on human health”.